To prospectively collect medical images and clinical data related to esophageal cancer using 4D Free Breathing DCE-MRI technology, to evaluate the image quality in the diagnosis of esophageal cancer, and to predict the efficacy of preoperative neoadjuvant chemoradiotherapy for esophageal cancer.
Be 18 years of age and older;
First diagnosis of esophageal squamous cell carcinoma confirmed by histopathological biopsy;
The clinical stage is cT1b~cT2N+; or the clinical stage is cT3~cT4 any N, (thoracic esophageal cancer, esophagogastric junction cancer);
There are no contraindications to MRI examination
Have other primary tumors;
The image quality does not meet the diagnostic criteria;
Those who do not cooperate with the inspection;
Patients who have received prior chemoradiotherapy
Single group
The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer
Diagnostic testChest MRI scan outside of standard treatment options
Tumor response assessment
This study aims to assess tumor treatment response using pathology gold standard pCR . pCR refers to the state in which the pathological tumor completely disappears after systemic therapy, such as chemotherapy, targeted therapy, or endocrine therapy.
Click on the lead sponsor to view all of their trials.
